

Development of Small Molecules with a Non-Canonical Binding Mode to HIV-1 Trans Activation Response (TAR) RNA

Fardokht A Abulwerdi, Matthew D Shortridge, Joanna Sztuba-Solinska, Robert Wilson, Stuart F.J. Le Grice, Gabriele Varani, and John S Schneekloth, Jr.

J. Med. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.jmedchem.6b01450 • Publication Date (Web): 16 Nov 2016

Downloaded from <http://pubs.acs.org> on November 16, 2016

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1
2 **Development of Small Molecules with a Non-Canonical Binding Mode to HIV-1 Trans Activation**
3 **Response (TAR) RNA**
4

5
6 Fardokht A. Abulwerdi,^{†,‡} Matthew D. Shortridge,[#] Joanna Sztuba-Solinska,[‡] Robert Wilson,[†] Stuart F. J.

7
8 Le Grice,[‡] Gabriele Varani,[#] and John S. Schneckloth, Jr.^{*,†}
9

10
11
12 [†]Chemical Biology Laboratory, National Cancer Institute, Frederick, Maryland 21702, USA

13
14 [‡]Basic Research Laboratories, National Cancer Institute, Frederick, Maryland 21702, USA

15
16 [#]Department of Chemistry, University of Washington, Seattle, Washington 98195, USA
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Keywords:

HIV-1 transactivation response RNA (TAR), RNA-binding small molecules, thienopyridine compounds, NMR, SHAPE.

Abstract

Small molecules that bind to RNA potently and specifically are relatively rare. The study of molecules that bind to the HIV-1 transactivation response (TAR) hairpin, a cis-acting HIV genomic element, has long been an important model system for the chemistry of targeting RNA. Here we report the synthesis, biochemical and structural evaluation of a series of molecules that bind to HIV-1 TAR RNA. A promising analog, **15**, retained the TAR binding affinity of the initial hit and displaced a Tat-derived peptide with an IC_{50} of 40 μ M. NMR characterization of a soluble analog, **2**, revealed a non-canonical binding mode for this class of compounds. Finally, evaluation of **2** and **15** by Selective 2'-hydroxyl acylation analyzed by primer extension (SHAPE) indicates specificity in binding to TAR within the context of an *in vitro*-synthesized 365-nt HIV-1 5'- untranslated region (UTR). Thus, these compounds exhibit a novel and specific mode of interaction with TAR, providing important implications for RNA ligand design.

Introduction

RNA-binding small molecules are an important and highly challenging area of therapeutic research. The discovery of non-coding RNAs and their widespread role in human disease strongly suggests that opportunities to redress disease conditions by targeting RNA should be plentiful.¹ Structural and analytical techniques over the last few decades have provided information about RNA structure and function, yet examples of small drug-like molecules that interact with RNA are still rare relative to proteins. The polyanionic nature of RNA, coupled with its highly flexible and dynamic structure and repetitive nature of its surface, present challenges for inhibitor design. Many known RNA-binding small molecules are polycationic, binding tightly (with K_d s in the mid nM range) but with limited specificity. Furthermore, they tend to be larger than desirable for typical drugs and do not satisfy the characteristic physicochemical properties of modern successful drug candidates.

1
2 A well-characterized system to study small molecule RNA antagonists is transactivation
3
4 response (TAR) element from HIV type 1 (HIV-1), a 59-nucleotide stem-loop RNA located in the 5'-
5
6 untranslated region (UTR) of the viral genome. TAR plays a pivotal role in HIV replication via its
7
8 interaction with Tat, a virus-encoded protein that recruits the host transcriptional machinery to facilitate
9
10 efficient transcription of the viral DNA.²⁻⁵ While the TAR structure is evolutionary conserved, sequence
11
12 heterogeneity exists among various virus isolates.⁶ However, in the case of HIV-1 subtypes, base pair
13
14 co-variations, e.g., A-U conversion into G-C has been shown to maintain TAR structural integrity.⁷ In
15
16 addition to being a transcriptional activator, TAR has also been shown to play a role in initiation of
17
18 reverse transcription.⁸⁻¹⁰ More recently, several groups have demonstrated that TAR also functions as a
19
20 miRNA that downregulates cellular apoptotic genes and leads to extended cellular proliferation and
21
22 continued virus production.¹¹⁻¹³ In sum, The central role of TAR in HIV-1 biology underscores its
23
24 potential as a therapeutic target.¹⁴ Thus, inhibition of the Tat-TAR interaction has been pursued as a
25
26 potential anti-HIV therapeutic strategy. While numerous classes of small molecules have been
27
28 reported¹⁵⁻¹⁷, the lack of anti-HIV drugs targeting TAR in the clinic highlights the challenges in
29
30 developing small molecule RNA binders. TAR RNA remains both an important anti-viral target and a
31
32 model system to develop RNA-targeting molecules.
33
34
35

36
37 Previously, we utilized a small molecule microarray (SMM) screening platform to rapidly screen
38
39 immobilized small molecules against nucleic acid targets.¹⁸ In one example, we reported the discovery
40
41 of **1**, a thienopyridine compound that interacts with the TAR hairpin.¹⁹ However, at that time little was
42
43 known about the mode of interaction between the compound and RNA. Here, we have developed a
44
45 chemical synthesis of **1** to generate a focused library of 25 compounds derived from the initial hit
46
47 structure. Biochemical and biophysical analyses of this series of compounds, including affinity
48
49 measurements, NMR analysis, and SHAPE, provided information about structure-activity relationships
50
51 as well as insights into the mode of binding of this class of compounds to HIV-1 TAR.
52
53
54
55
56
57
58
59
60

Results and Discussion

Chemistry

To prepare a focused compound library, we developed a modular and convergent synthetic route to **1** and its analogs. For preparation of **1**, 2-chloro-6-methylnicotinonitrile (**24**) was treated with thiourea in refluxing n-butanol to provide 2-mercapto-6-methylnicotinonitrile (**25**) in essentially quantitative yield (Scheme 1).²⁰ In parallel, reaction of 3-(trifluoromethyl)aniline (**26**) with bromoacetyl bromide in the presence of catalytic amounts of 4-N,N-dimethylamino-pyridine (DMAP) provided 2-bromo-N-(3-(trifluoromethyl)phenyl)acetamide (**27**) in high yield (Scheme 1).²¹ Reaction of mercaptopyridine **25** with bromoacetamide **27** in refluxing ethanol in the presence of excess sodium ethoxide promoted bromide displacement by the thiol group of the mercaptopyridine intermediate followed by cyclization to afford the thienopyridine ring structure, providing **1** in 58% yield (Scheme 1).²²

We next used this route to design and synthesize several analogs of **1** to evaluate how structural changes would affect affinity for TAR. **2-4**, containing a second pyridine ring, were prepared by reaction of the associated aminopyridines (**28g-i**) with bromoacetyl bromide to provide the bromoacetamide as an HBr salt (**29g-i**) (Scheme 2A).²³ Treatment of bromoacetamides **29g-i** with 2-mercapto-6-methylnicotinonitrile (**25**) in refluxing ethanol in the presence of excess base yielded the assembled thienopyridine ring system (Scheme 2A). **5-9** were prepared via a similar synthetic route to **1** (Scheme 2B). In the case of **10**, with a bulkier isopropyl group at the 6-position of the pyridine core, reaction of 2-chloro-6-isopropylnicotinonitrile (**30c**) with thiourea failed to yield the desired mercaptopyridine. Therefore, Lawesson's reagent was used to synthesize the desired mercaptopyridine (**31c**) in modest yield.²⁴ The reaction of mercaptopyridine **31c** with the desired bromoacetamide (**27**) proceeded as described for **1** to provide **10** (Scheme 2B). Preparation of **11**, lacking an amine, was achieved by a modified Sandmeyer reaction, employing NaNO₂/H₂SO₄/Cu₂O with hypophosphorous acid (Scheme 3).²⁵ Additionally, reaction of **1** with triphosgene at room temperature provided cyclized **12** (Scheme 3).²⁶ Analogs containing a sulfonamide linker were synthesized by the reaction of desired anilines (**26** and **34**) and chloromethanesulfonyl chloride in the presence of triethylamine followed by a

1 basic workup²⁷ to provide the sulfonamide intermediate (**35-36**) (Scheme 3). Sulfonamides **35-36** were
2 treated with the desired mercaptopyridine (**25**) in the presence of excess base in N,N-dimethylformamide
3 (DMF) at 130 °C to afford **13** and **14** (Scheme 3).²⁷
4
5
6
7

8 We also prepared **15-19**, containing oxadiazolyl linkers between the thienopyridine core and the
9 aryl group (Scheme 4). For **15** and **16**, which contain 1,3,4-oxadiazol-2,5-yl and 1,2,4-oxadiazol-3,5-yl
10 rings (respectively), commercially available chloromethyl phenyl substituted oxadiazoles (**37l-m**) were
11 treated with 2-mercapto-6-methylnicotinonitrile (**25**) in the presence of excess base in DMF at 130 °C,
12 producing the thienopyridine scaffold in good yield. **17-23** were synthesized similar to **16** (Scheme 4
13 and Scheme S1). In the case of **24-26**, the desired chloromethyloxadiazoles were conveniently
14 prepared as reported previously²⁸ and further treated with **25** to yield the desired products (Scheme
15 S2). Collectively, the convergent route reported here furnished a library of 25 analogs of the initial hit
16 structure.
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **Biochemical evaluation of compound library**

31 **a. Affinity measurement**

32 To evaluate the TAR binding properties of analogs described above, we utilized a series of
33 biochemical assays that provide information on both compound affinity for TAR and its ability to
34 displace a Tat-derived peptide from TAR, revealing a clear picture of structure-activity relationship. To
35 probe direct binding of compounds to TAR, we utilized two different 2-aminopurine (2-AP) assays. 2-
36 AP is an environmentally-sensitive fluorophore that reports on the local environment of the base.²⁹
37 Conformational changes in the RNA upon binding of a ligand result in changes in fluorescence
38 intensity, which can be used to derive accurate affinities. Two distinct constructs were used where
39 either U25 or U23 (both of which are located in the bulge region of TAR hairpin) was replaced with a 2-
40 AP fluorophore (Figure 1A). U25 is a flexible residue³⁰ and its replacement by 2AP has been previously
41 utilized in probing TAR-ligand interactions²⁹. To evaluate larger numbers of compounds, we
42 miniaturized the 2-AP assay to be compatible with plate reader-based analysis. This format required a
43 higher concentration of RNA, but enabled a significantly reduced assay volume of 100 μ L per sample in
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 a 96 well plate. Once optimized, this assay generated reproducible apparent binding constants (K_{dapp}),
2
3
4 albeit with slightly higher values than obtained under previous assay conditions.¹⁹ Values obtained
5
6 under these conditions were both internally consistent and comparable to recently published K_d s of
7
8 several TAR-binding small molecules.³¹
9

10 K_{dapp} obtained from 2-AP assays with both constructs were in good agreement (Table 1).
11
12 Synthetic **1** showed an apparent $K_{dapp 25-2AP}$ of $47.7 \pm 11.6 \mu\text{M}$. Next, the trifluoromethylphenyl group
13
14 was replaced by different pyridine isomers (**2-4**) which dramatically improved compound solubility,
15
16 making them usable at high concentrations in NMR experiments (see below). Interestingly, analog **2**,
17
18 containing 4-pyridyl substitution, exhibited a similar binding affinity ($K_{dapp 25-2AP} = 40.0 \pm 0.7 \mu\text{M}$) to **1**
19
20 (Figure 1B). Analogs **3**, containing 3-pyridyl ($K_{dapp 25-2AP} = 68.0 \pm 26.0 \mu\text{M}$) and **4** with 2-pyridyl ($K_{dapp 25-}$
21
22 $2AP = 50.3 \pm 10.3 \mu\text{M}$) substituents showed ~2-fold weaker binding affinity compared to **2**. Changing the
23
24 position of the *meta*-trifluoromethyl group in **1** to *para* (**7**, $K_{dapp 25-2AP} = 75.3 \pm 9.2 \mu\text{M}$) or *ortho* (**8**, $K_{dapp 25-}$
25
26 $2AP = 90.1 \pm 4.7 \mu\text{M}$) decreased binding affinity approximately 2-fold. Additionally, extending the *meta*-
27
28 trifluoromethyl phenyl by a methylene linker (**9**, $K_{dapp 25-2AP} = 66.4 \pm 0.9 \mu\text{M}$) maintained a similar binding
29
30 affinity to **1**.
31
32

33
34 We further investigated the role of substitution on the pyridyl ring of thienopyridine scaffold.
35
36 Moving the methyl group to the 5-position (**6**, $K_{dapp 25-2AP} = 48.5 \pm 5.4 \mu\text{M}$) maintained a similar binding
37
38 affinity as **1** while the 4-methyl substituent (**5**, $K_{dapp 25-2AP} = 66.5 \pm 4.5 \mu\text{M}$) showed ~2-fold weaker
39
40 binding affinity. Replacing the methyl substituent with a bulkier isopropyl group in **10** ($K_{dapp 25-2AP} = 43.3$
41
42 $\pm 13.3 \mu\text{M}$) maintained similar affinity compared to **1**. Next, Analog **11**, a desamino thienopyridine,
43
44 showed inferior binding affinity, highlighting the importance of the amino group. Additionally, replacing
45
46 amide for a sulfonamide in analog **13** and **14** or a cyclized analog, **12**, completely abolished binding.
47
48

49
50 Next, we evaluated the oxadiazole series. Interestingly, isosteric replacement of the amide
51
52 linker in **1** with 1,3,4-oxadiazol-2,5-yl in **15** ($K_{dapp 25-2AP} = 49.1 \pm 7.8 \mu\text{M}$) (Figure 1B) as well as 1,2,4-
53
54 oxadiazol-3,5-yl in **16** ($K_{dapp 25-2AP} = 47.7 \pm 17.8 \mu\text{M}$) retained binding affinity as observed for **1**. Analogs
55
56 **17-19**, containing the 1,3,4-oxadiazol-2,5-yl but with different substitution pattern, retained the binding
57
58
59
60

1
2 affinity of **15**. However, evaluation of 1,3,4-oxadiazol-2,5-yl analogs **20-26** either decreased solubility or
3
4 abolished binding affinity (Table S1).

6 **b. Competitive binding assay measurements**

7
8 In addition to the 2-AP direct binding assays, we utilized an orthogonal FRET-based assay to
9
10 evaluate disruption of the Tat-TAR interaction.³² In this assay, a 16-mer peptide derived from Tat
11
12 protein is labeled with fluorescein at its N-terminus and TAMRA at its C-terminus. In solution, the two
13
14 fluorophores in the free peptide are in close proximity and quench each other. Upon binding to TAR,
15
16 the peptide adopts an extended conformation, inducing FRET. In this assay, a compound capable of
17
18 disrupting the Tat-TAR interaction will cause a loss of FRET signal. All synthesized analogs were
19
20 evaluated in FRET assay. While many, including **2**, did not display activity in this assay up to 400 μM , it
21
22 is notable that oxadiazole analogs **15** (Figure 1C) and **16** ($\text{IC}_{50} = 40.1 \pm 5.6 \mu\text{M}$ and $\text{IC}_{50} = 45.1 \pm 25.8$
23
24 μM respectively) displaced the Tat peptide with IC_{50} values similar to their apparent K_{d} s (Table 1).
25
26 Additionally, while removal of *meta*-trifluoromethyl group on the phenyl ring in **17** or its replacement with
27
28 *meta*-chloro in **18** abolished FRET signal, the absence of 6-methyl substituent in **19** maintained FRET
29
30 activity similar to **15** (Table 1) suggesting the importance of phenyl substituent on the ability of the
31
32 oxadiazole analogs to displace the Tat peptide.
33
34
35

36
37 Taken together, our thienopyridine analogs displayed mid micromolar binding to the TAR hairpin
38
39 under the assay conditions. While the majority of the structural changes in this study resulted in subtle
40
41 effects, isosteric replacement of the amide with oxadiazoles provided analogs which not only
42
43 maintained binding affinity to TAR but displaced the Tat peptide in the FRET assay at concentrations in
44
45 the mid micromolar range. It is also noteworthy that the compounds in this series with similar binding
46
47 affinity show differing behavior in the FRET-based assay. However, these observations are consistent
48
49 with a report in which peptides with similar TAR binding affinity also exhibited very different IC_{50} values
50
51 in displacing a Tat peptide.³³ This seemingly contradictory observation suggests that the determinants
52
53 of binding may differ from those required for disrupting an associated RNA/peptide interaction, at least
54
55 for some ligands.
56
57
58
59
60

NMR studies

To better understand the mode of interaction of the compounds with TAR, we investigated the small molecule-RNA complex by NMR. Many compounds in this series exhibited poor aqueous solubility, which limited high-resolution structure analysis. Compound **2** displayed increased solubility relative to **1** and could be studied at concentrations amenable for ligand-detected NMR experiments and some limited RNA-detected experiments. **2** was first evaluated using line broadening methods (Figure 2A and Figure S1A-C).³⁴ In this experiment, its proton spectra was recorded in the presence and absence of 10 μ M TAR. Upon binding, the ligand resonances broaden in response to the increase in rotational correlation time while bound to target RNA.³⁴ In the case of **2**, the two doublets corresponding to protons on the pyridine ring of the thienopyridine scaffold (protons a and b in Figure 2A) are completely broadened in presence of TAR suggesting the pyridine ring directly interacts with the hairpin while other proton peaks do not change (Figure S1A). In contrast, ligand-detected NMR of a non-binding analog **14** shows no line broadening in neither the aromatic (Figure 2B) nor aliphatic region (Figure S1B). The line-broadening pattern in the 1D-¹H NMR experiments is consistent with the 2-AP fluorescent-based affinity measurements indicating mid micromolar binding.

Ligand-detected NMR experiments require lower ligand concentration to measure binding, which is useful for low solubility molecules. However, these methods are also susceptible to non-specific aggregation effects, which generate false positive results. Therefore, to identify and verify binding of **2**, we evaluated ligand-induced chemical shift perturbations in total correlation spectroscopy (TOCSY) experiments. Here, free TAR hairpin was evaluated upon the addition of **2** (Figure 3A-B and Figure S1D-E). Specific changes in the TOCSY spectrum suggest single site binding with the largest changes occurring at bases C39, U40 and C41. These residues are located directly below the -UCU-bulge residues U23, C24 and U25. Resonances within residues U23 and C24 also show significant chemical shift changes. However, unlike many TAR ligands, U25 does not show significant changes in chemical shift, nor do any of the remaining pyrimidines, indicating a new binding mode compared to previously reported TAR-binding ligands such as argininamide and acridine, which disrupt stacking of A22 and U23 and bind to the major groove of TAR similar to Tat-derived peptides.³⁵⁻³⁷ On the other

1 hand, the solution NMR structure of Neomycin B bound to TAR indicates that this aminoglycoside binds
2 in the minor groove instead.³⁸ However TAR residues G21, U42 and G26 that are shifted in presence of
3 Neomycin B are not the same residues perturbed by **2**. Additionally, Hoescht 33258 has been reported
4 to bind to the TAR hairpin, though it binds to the major groove/upper bulge region primarily at and
5 around bases G36-U40.³⁹

6 The concentration-dependent chemical shift perturbations of TAR residues induced by **2**
7 suggest that complex formation occurs in the fast exchange regime of the NMR time scale. However,
8 residues U40 and C41 also experience broadening in addition to chemical shift changes specific to
9 these residues. These results are entirely consistent with binding in the mid micromolar range, in
10 agreement with binding affinity determined by biochemical assays. The perturbed residues are
11 concentrated in the bulge and lower bulge region of the TAR hairpin, suggesting that **2** may be a lower
12 bulge binder.

13 In sum, the NMR studies indicate that **2** binds to TAR and is likely a lower bulge/minor groove
14 binder. This binding mode does not perturb many residues in the Tat binding site itself, which provides
15 insight into the varying ability of compounds in this series to displace the Tat peptide. Attempts to derive
16 a full structure of TAR bound to **2** by intermolecular NOESY experiments were hampered by the limited
17 solubility of the ligand under the required NMR conditions.

40 **SHAPE**

41 Selective 2'-hydroxyl acylation analyzed by primer extension (SHAPE) can be used to establish
42 RNA secondary structure and identify sites of interaction of RNA with other molecules by examining
43 backbone flexibility.⁴⁰ Electrophilic reagents, e.g. 1M7 (1-methyl-7-nitroisatoic anhydride) modify the 2'-
44 OH of less-structured RNA nucleotides, which causes reverse transcription (RT) to halt one nucleotide
45 before the modification. Modification frequencies are then used to estimate a 'reactivity profile' that
46 quantifies the propensity of each nucleotide to be modified by the chemical probe. High reactivity
47 reflects nucleotides that are flexible and unstructured, while low reactivity provides structural
48 constraining, such as formation of base pairing, stacking or RNA–ligand interactions.

1 We applied SHAPE to probe RNA conformational changes that would be diagnostic of
2 compound binding in the context of an *in vitro*-synthesized 365-nt HIV-1 5' UTR RNA. Changes in 1M7
3 reactivity at each nucleotide of the HIV-1 5' UTR RNA in the presence of **2** and **15** are presented in
4 Figure 4 (relative to the analogous experiment performed in its absence). The *decrease* in nucleotide
5 reactivity upon analog addition is indicated in gradients of blue, while *increase* in reactivity is
6 represented in gradients of red; unchanged nucleotide reactivity is in gray. While the global topology of
7 the 5' UTR was unaffected upon incubation with **2** and **15**, substantial changes in chemical reactivity
8 were observed mostly within TAR (Figure 4A-B). In particular, addition of **2** caused a decrease in 1M7
9 reactivity for residue U25 within the TAR bulge and U31, G33 and A35 within the apical loop (Figure
10 4A). Reactivity changes observed in the apical loop residues for **2** could reflect ligand binding to the
11 lower bulge region (as discussed above) causing disruption of a direct interaction between the apical
12 loop and the bulge as recently demonstrated by Krawczyk et al.⁴¹ Addition of **15** to RNA showed a
13 similar 1M7 reactivity reduction throughout TAR compared to **2**, and in particular with residues U13-14,
14 C19 and G32 (Figure 4B). Taken together, reduced 1M7 reactivity suggests that analog binding causes
15 structural perturbations to TAR due to a direct or, for loop residues, indirect interaction with **2** and **15**.
16 Furthermore, these results are consistent with our observations for **1**, which we showed also bound
17 selectively to the TAR hairpin.¹⁹ Although the global topology of the 5' UTR was unchanged upon
18 compound binding, subtle changes in chemical reactivity were observed downstream of the TAR
19 hairpin. These "off target" effects may reflect the influence of compound binding on long-range tertiary
20 interactions^{42, 43} and/or indirect structural rearrangements in the 5' UTR.⁴⁴ In conclusion, the SHAPE
21 data suggest specific binding of both **2** and **15** to the TAR region of HIV-1 UTR in the presence of other
22 structured motifs.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 Conclusions

53 We have characterized the interaction of a series of thienopyridine compounds to the HIV-1
54 TAR RNA hairpin. The initial structure, **1**, was discovered in a screen of immobilized small molecules,
55 which identified several structures binding to TAR specifically over other RNA stem-loops. Compound **1**
56
57
58
59
60

1 and a focused library of 25 analogs were synthesized using a concise and modular synthetic route.
2
3 These compounds were then evaluated in several biochemical assays for binding to the TAR hairpin as
4
5 well as to disrupt the Tat-TAR interaction. A clear structure-activity relationship was observed in the
6
7 binding assays. A number of analogs, but not all those that bound to TAR, were able to displace a Tat-
8
9 derived peptide from the RNA. Replacing the amide linker with either of two oxadiazolyl groups yielded
10
11 analogs with similar affinity to the original hit that were also able to disrupt the Tat/TAR interaction. The
12
13 most potent analog, **15**, showed a similar binding affinity to **1** and exhibited an IC₅₀ of 40 μM for
14
15 displacement of Tat-derived peptide. SHAPE studies showed that both **2** and **15** retained global
16
17 specificity for binding to the TAR motif within the 365-nt HIV-1 5' UTR RNA. NMR studies further
18
19 confirmed that **2** binds to TAR and causes chemical shift perturbations exclusively within and below the
20
21 bulge region. These results suggest that **2** binds to the lower bulge region, possibly within the minor
22
23 groove. The perturbed residues differ from those interacting with a Tat-derived peptide, neomycin,
24
25 Hoechst 33258 or argininamide, which could provide a basis for the varying ability of compounds in this
26
27 class to displace the peptide. Future efforts will focus on improving solubility of analogs for cell-based
28
29 studies and further development of a bifunctional molecule to tether our lower bulge binder with an
30
31 apical loop binder such as 5-(N,N)-dimethyl amiloride³¹ to achieve both increased specificity and
32
33 enhanced affinity through synergistic binding.
34
35
36
37
38
39
40

41 **Experimental Section**

42 **Biochemical assays**

43
44 Nucleic acids were purchased from Dharmacon with the following sequences:
45
46

47
48 TAR RNA: 5'-GGCAGAUCUGAGCCUGGGAGCUCUCUGCC-3' and 25-2AP TAR: 5'-
49
50 GGCAGAUC(2AP)GAGCCUGGGAGCUCUCUGCC-3 and 23-2AP TAR: 5'-
51
52 GGCAGA(2AP)CUGAGCCUGGGAGCUCUCUGCC-3. TAR and 2AP TAR constructs were
53
54 reconstituted in 1x PBS pH 7.4 to a concentration of ~100 μM and annealed by heating to 95 °C for 3
55
56 min. The constructs were allowed to cool to room temperature for at least 30 min. Tat FRET peptide, a
57
58
59
60

1
2 16-mer peptide labeled at its N-terminus by FAM and C-terminus by TAMRA, was purchased from
3 AnaSpec (catalog #: AS-64346-05). A fluorescence-based assay employing TAR constructs labeled
4 with 2-AP either at bulge residues U23 or U25 was used. 2-AP TAR constructs were used at 1 μ M. 5
5 μ L of the tested compound in DMSO and 95 μ L of 2-AP TAR in the assay buffer (1x PBS pH 7.4) were
6 added to assay plate (Nunc black plates) and incubated at room temperature with rocking for 30 min.
7
8 Fluorescence values were measured at an excitation wavelength of 310 ± 9 nm and an emission
9 wavelength of 365 ± 9 nm using a microplate reader and values were normalized to free 2-AP TAR.
10
11 Most analogs were not fluorescent at this wavelength, and in the case of fluorescent compounds, the
12 inherent fluorescence was subtracted from that of the complex (TAR and compound) and then
13 normalized to free 2-AP TAR. Apparent K_d values were determined by non-linear regression by fitting
14 the measured fluorescence (GraphPad Prism 6.0 software). FRET studies were performed as
15 previously reported³² with modification. Unlabeled TAR was used at 100 nM and FAM-Tat-TAMRA at
16 12 nM. 5 μ L of the tested compound (in DMSO) and 95 μ L of unlabeled RNA/peptide complex in assay
17 buffer (50 mM Tris pH 7.4; 20 mM KCl; 0.01% Triton X-100) were added to Nunc black assay plates
18 and incubated at room temperature for 30 min with rocking. It should be noted that each plate
19 contained four wells for negative control (equivalent to 0% inhibition and highest fluorescent/FRET)
20 which included 100 nM unlabeled TAR and 12 nM FAM-Tat-TAMRA in presence of 5% DMSO.
21 Additionally, three wells were assigned for the positive control (equivalent to 100% inhibition and
22 lowest fluorescence/FRET) which included 12 nM of FAM-Tat-TAMRA in presence of 5% DMSO.
23 Fluorescence values were measured at an excitation wavelength of 485 ± 20 nm and an emission
24 wavelength at 590 ± 35 nm using a microplate reader. Most analogs were not fluorescent at this
25 wavelength; however for analogs **2**, **3**, **4**, **16**, **23** and **25**, the fluorescence of complex (unlabeled
26 TAR/labeled Tat) in presence of compound exceeded the maximum fluorescence as indicated by the
27 negative control wells. Therefore, the inherent fluorescence of compound was subtracted from that of
28 the complex plus compounds. IC_{50} values were determined by non-linear regression fitting of the
29 competition curves.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

NMR

HIV-1 TAR RNA hairpin was transcribed and purified as described previously.⁴⁵⁻⁴⁷ Ligand detected NMR experiments were collected on a Bruker DRX 500MHz equipped with TCI cryoprobe or Bruker Avance III 600 MHz spectrometer equipped with TCI cryoprobe. NMR screening buffer consisted of 20 mM d₁₉-Bis-Tris at pH6.5, 10 mM sodium chloride, and 11.1 μM DSA as chemical shift reference (integrates to 100 μM)⁴⁸, prepared in 99.99% D₂O or 95%H₂O/5%D₂O. Each ligand was first dissolved in DMSO to a 10 mM stock concentration in d₆-DMSO. Free ligand screening samples were prepared at 150 μM in NMR screening buffer with final DMSO concentration of 15%. We used this concentration as the safe upper limit beyond which the RNA structure might be affected. For RNA detected experiments, the lyophilized RNA pellets were dissolved in DMSO-free NMR screening buffer and heated for 4 min at 90°C, then snapped cooled for 5 min at -20 °C. 1D-1H experiments for both ligand and RNA were collected using the Bruker “zgesgp” excitation sculpting pulse sequence to suppress background water signal. Data was collected with 64 scans and 16K data points. Data was processed using 16K zero points, Fourier transformed followed by manual phase and baseline correction. 2D-1H TOCSY experiments were collected using the Bruker “mlevesgp” pulse sequence with excitation sculpting water suppression, data collected with 8 scans, 2K x 512 data points, a recycle delay of 1.2 s and spin-lock mixing time of 80ms. Data was processed using NMRPipe and visualized using SPARKY.

SHAPE

RNA preparation for SHAPE analysis - DNA template for *in vitro* transcription were generated by PCR amplification of the HIV-1 molecular clone pNL4-3 using the following primers:

T7L 5'- TAATACGACTCACTATAGGTCTCTCTG - 3' (containing T7 promoter, underlined)

369R 5'- GCTTAATACCGACGCTCTCGC - 3'

All PCR experiments were performed using Invitrogen Platinum® Taq DNA polymerase High Fidelity. Transcripts were synthesized with the MEGAscript T7 transcription kit (Thermo Fisher Scientific) following the manufacturer's protocol, and RNAs were purified from denaturing 8 M urea/6% polyacrylamide gels, followed by electro-elution and ethanol precipitation. Purified RNAs were dissolved in sterile water and stored at -20 °C.

1
2
3
4 **Renaturation and 1M7 treatment of RNA** - 5 pmoles of RNA were heated to 90 °C for 3 min, and
5
6 gradually cooled to 4 °C (0.1 °C/sec). The volume was adjusted to 10 µL in a final buffer of 50 mM Tris-
7
8 HCl (pH 8.0), 100 mM NaCl, 5 mM MgCl₂. Samples were then divided into 5 µl experimental (+) and
9
10 control (-) aliquots (2.5 pmoles each) and incubated at 37 °C for 15 min. Analog **2** and **15** were added
11
12 to both (+) and (-) RNA solutions to a final concentration of 5 µM and 0.5 µM respectively, and
13
14 incubated for 10 min at room temperature. Chemical modification was initiated by addition of 1 µL of
15
16 1M7 (in anhydrous DMSO) to the (+) RNA solution to a final concentration of 3.5 mM, or DMSO alone
17
18 to the (-) RNA reaction, followed by incubation at 37 °C for 5 min. Completed reactions were
19
20 precipitated at -20 °C with 10 ng/µL glycogen, 0.3M sodium acetate pH 5.2 and 2.5 volumes of cold
21
22 ethanol. RNA was collected by centrifugation, and resuspended in 10 µL of water. A parallel experiment
23
24 lacking analogs was performed as a control.
25
26
27
28
29

30 **Primer extension** - For detection of 2'-O-adducts, 2.5 pmoles of modified and unmodified RNAs were
31
32 mixed, respectively, with 5 pmoles of Cy5-labelled (for 1M7-modified samples) or 6 pmoles of Cy5.5-
33
34 labelled (for unmodified samples) DNA primer complementary to their 3' end. Samples were incubated
35
36 at 85 °C for 1 min, 60 °C for 5 min, 35 °C for 5 min and 50 °C for 2 min to anneal primers to initiate
37
38 reverse transcription. RNA was reverse transcribed at 50 °C for 50 min with 100U RT (Invitrogen
39
40 Superscript III), 1x RT buffer (Invitrogen), 5 mM DTT and 500 mM dNTPs (Promega). RNA was
41
42 hydrolyzed with 200 mM NaOH for 5 min at 95 °C and samples were neutralized with an equivalent
43
44 volume of HCl. Sequencing ladders were prepared using the Epicentre cycle sequencing kit according
45
46 to the manufacturer's instructions and primers labeled with WELLRed D2 and LICOR IR-800 dyes.
47
48 Modified and control samples were mixed with the sequencing ladders, precipitated as above, dried
49
50 and resuspended in 30 µL deionized formamide. Primer extension products were analyzed on a
51
52 Beckman CEQ8000 Genetic Analysis System programmed with the separation method described
53
54 previously.⁴⁹
55
56
57
58
59
60

1 **SHAPE data analysis** - Electropherograms were processed using the program SHAPEfinder program,
2 following the software developer's protocol and included the required pre-calibration for matrixing and
3 mobility shift for each set of primers as described.^{40, 50} The area under each negative peak was
4 subtracted from that of the corresponding positive peak. The resulting peak area difference at each
5 nucleotide position was then divided by the average of the highest 8% of peak area differences,
6 calculated after discounting any results greater than the 3rd quartile plus 1.5x the interquartile range.
7 RNAstructure software version 5.7 was used to predict RNA secondary structure(s) on the basis of
8 pseudo-free energy constraints derived from SHAPE reactivity values. All reactivity data used in 2D
9 structure analysis was averaged from three independent experiments. Varna (ver. 3-9), the
10 visualization applet for RNA secondary structure, was used to produce high-quality images.⁵¹

24 **Chemistry**

26 Chemicals were purchased from commercial sources and used without further purification unless
27 otherwise noted. Anhydrous solvents were prepared by passage over activated alumina. Thin-layer
28 chromatography was conducted with E. Merck silica gel 60 F254 precoated plates (0.25 mm) and
29 visualized by exposure to UV light (254 nm). Flash column chromatography was performed using
30 normal phase or reverse phase on a CombiFlash® Rf 200i (Teledyne Isco Inc). ¹H NMR spectra
31 were recorded at 400 or 500 MHz, and are reported relative to deuterated solvent signals. Data for
32 ¹H NMR spectra are reported as follows: chemical shift (δ ppm), multiplicity, coupling constant (Hz),
33 and integration. ¹³C NMR spectra were recorded at 100 or 125 MHz. Data for ¹³C NMR spectra are
34 reported in terms of chemical shift. All NMR spectra were standardized to the NMR solvent signal
35 as reported previously.⁵² Analytical LC/MS was performed using a Shimadzu LCMS-2020 Single
36 Quadrupole utilizing a Kinetex 2.6 μ m C18 100 Å (2.1 x 50 mm) column obtained from
37 Phenomenex Inc. Runs employed a gradient of 0→90% ACN/0.1% aqueous formic acid over 4
38 minutes at a flow rate of 0.2 mL/min. Purities of final compounds were assessed by analytical reverse-
39 phase HPLC using Agilent Proshell 120 EC-C18 (4.6 mm x 50 mm; particle size 2.7 μ m). Runs
40 employed a gradient of 10% ACN/water (1 min), 10-90% ACN/water (6 min), and 90% ACN/water (2
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

min) flow = 1 mL/min. High-resolution LC/MS analyses acquired on an Agilent 6520 Accurate-Mass Q-TOF LC/MS System, (Agilent Technologies, Inc., Santa Clara, CA) equipped with a dual electro-spray source, operated in the positive-ion mode. Separation was performed on Zorbax 300SB-C18 Poroshell column (2.1 mm x 150 mm; particle size 5 μ m). All final compounds were purified to >95% purity unless otherwise stated.

Representative procedure for thienopyridine carboxamide preparation

3-Amino-6-methyl-*N*-(3-(trifluoromethyl)phenyl)thieno[2,3-*b*]pyridine-2-carboxamide (1).

Synthesized using reported procedure with modification.²² To a suspension of **25** (51 mg, 0.34 mmol) in anhydrous EtOH (2 mL) was added **27** (92 mg, 0.32 mmol) and sodium ethoxide (54 mg, 0.75 mmol). The mixture was heated to reflux for 1 h 15 min. The mixture was diluted with EtOAc (10 mL) and washed with H₂O (10 mL x 2) and brine (10 mL). The organic layer was dried (Na₂SO₄), filtered, and concentrated *in vacuo*. Crude was purified by flash column chromatography (hexanes/EtOAc) on silica gel to give **1** (65 mg, 58%) as a light yellow solid. Purity 100%. ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.70 (s, 1H), 8.41 (d, *J* = 8.3 Hz, 1H), 8.23 (s, 1H), 7.99 (d, *J* = 8.3 Hz, 1H), 7.56 (t, *J* = 8.0 Hz, 1H), 7.47 (s, 2H), 7.41 (d, *J* = 7.7 Hz, 1H), 7.35 (d, *J* = 8.3 Hz, 1H), 2.61 (s, 3H). ¹³C NMR (125 MHz, DMSO-*d*₆) δ 164.23, 159.90, 158.54, 147.83, 140.00, 131.15, 129.58, 129.14 (q, *J* = 31.5 Hz), 125.31 (q, *J* = 272.4 Hz), 124.20, 123.60, 119.61, 119.41 (q, *J* = 3.8 Hz), 116.81 (q, *J* = 4.0 Hz), 94.75, 24.29. ESI HRMS: *m/z* 352.07332 (M+H)⁺.

Representative procedure for pyridinylthienopyridine carboxamide preparation

3-Amino-6-methyl-*N*-(pyridin-4-yl)thieno[2,3-*b*]pyridine-2-carboxamide (2). Synthesized using a similar procedure used to prepare **1** except using **29g**. Mixture was heated to reflux overnight. Upon cooling to room temperature and addition of H₂O, yellow solid precipitated. Solid was filtered and washed with cold EtOH. Crude was purified by flash column chromatography (hexanes/EtOAc) on silica gel to give **2** (18 mg, 22% over two steps) as a yellow solid. Purity 100%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.72 (s, 1H), 8.44 – 8.38 (m, 3H), 7.76 (d, *J* = 6.3 Hz, 2H), 7.53 (s, 2H), 7.35 (d, *J* = 8.3 Hz, 1H), 2.60 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 164.49, 160.15, 158.63, 149.99, 148.33, 146.11, 131.24, 123.44, 119.65, 114.19, 94.63, 24.29. ESI HRMS: 285.08048 (M+H)⁺.

6-Methyl-2-(pyridin-3-ylcarbamoyl)thieno[2,3-*b*]pyridin-3-aminium 2,2,2-trifluoroacetate (3).

Synthesized using a similar procedure used to prepare **1** except using **29h**. Mixture was heated to reflux overnight. Upon cooling to room temperature and addition of H₂O, yellow solid precipitated. Solid was filtered and washed with H₂O to give the title compound (26 mg, 46%) as a light yellow solid. Purity 98%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.60 (s, 1H), 8.88 (d, *J* = 2.2 Hz, 1H), 8.39 (d, *J* = 8.3 Hz, 1H), 8.27 (dd, *J* = 4.7, 1.4 Hz, 1H), 8.11 – 8.06 (m, 1H), 7.43 (s, 2H), 7.38 – 7.32 (m, 2H), 2.60 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 164.21, 159.84, 158.52, 147.61, 144.13, 142.59, 135.73, 131.12, 127.95, 123.60, 123.27, 119.59, 94.87, 24.27. ESI HRMS: 285.08043 (M+H)⁺.

3-Amino-6-methyl-*N*-(pyridin-2-yl)thieno[2,3-*b*]pyridine-2-carboxamide 2,2,2-trifluoroacetate (4).

Synthesized using a similar procedure used to prepare **1** except using **29i**. Mixture was heated to reflux overnight. Upon cooling to room temperature and addition of H₂O, yellow solid precipitated. Solid was filtered and washed with cold EtOH. Crude was purified by flash column chromatography (hexanes/EtOAc) on silica gel to give **4** (18 mg, 32%) as a yellow solid. Purity 100%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.54 (s, 1H), 8.39 (d, *J* = 8.3 Hz, 1H), 8.35 (d, *J* = 4.4 Hz, 1H), 8.05 (d, *J* = 8.3 Hz, 1H), 7.83 – 7.77 (m, 1H), 7.42 (s, 2H), 7.34 (d, *J* = 8.3 Hz, 1H), 7.12 (dd, *J* = 6.8, 5.2 Hz, 1H), 2.60 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 163.99, 159.86, 158.62, 151.96, 147.88, 147.62, 137.86, 131.15, 123.66, 119.51, 119.35, 114.70, 95.67, 24.28. ESI HRMS: 285.08095 (M+H)⁺.

3-Amino-4-methyl-*N*-(3-(trifluoromethyl)phenyl)thieno[2,3-*b*]pyridine-2-carboxamide (5).

Synthesized using a similar procedure used to prepare **1** except using **31a**. Crude was purified by flash column chromatography (hexanes/EtOAc) on silica gel to give **5** (44 mg, 37%) as a light yellow solid. Purity 96%. ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.78 (s, 1H), 8.49 (d, *J* = 4.7 Hz, 1H), 8.17 (s, 1H), 8.00 (d, *J* = 8.3 Hz, 1H), 7.57 (t, *J* = 8.0 Hz, 1H), 7.43 (d, *J* = 7.8 Hz, 1H), 7.21 (d, *J* = 5.4 Hz, 1H), 7.08 (s, 2H), 2.81 (s, 3H). ¹³C NMR (125 MHz, DMSO-*d*₆) δ 164.40, 159.28, 150.00, 149.70, 145.16, 139.76, 129.64, 129.19 (q, *J* = 31.0 Hz), 125.28, 124.93, 124.49, 123.12, 122.01, 119.69, 117.08, 96.93, 20.00. ESI HRMS 352.07318 (M+H)⁺.

3-Amino-5-methyl-*N*-(3-(trifluoromethyl)phenyl)thieno[2,3-*b*]pyridine-2-carboxamide (6).

Synthesized using a similar procedure used to prepare **1** except using **31b**. Crude was purified by silica

1 gel chromatography (hexanes/EtOAc) to give **6** (36 mg, 30%) as a light yellow solid. Purity 99%. ¹H
2 NMR (500 MHz, DMSO-*d*₆) δ 9.72 (s, 1H), 8.55 (s, 1H), 8.36 (s, 1H), 8.21 (s, 1H), 7.99 (d, *J* = 8.1 Hz,
3 1H), 7.56 (t, *J* = 7.9 Hz, 1H), 7.46 – 7.39 (m, 3H), 2.43 (s, 3H). ¹³C NMR (125 MHz, DMSO-*d*₆) δ
4 164.17, 156.13, 151.54, 147.34, 139.93, 130.86, 129.60, 129.16 (q, *J* = 31.4 Hz), 128.89, 125.80,
5 124.24, 124.22 (q, *J* = 272.2 Hz), 119.49 (d, *J* = 3.5 Hz), 116.85 (q, *J* = 3.8 Hz), 96.12, 17.96. ESI
6 HRMS: 352.07272 (M+H)⁺.
7

14 **3-amino-6-methyl-*N*-(4-(trifluoromethyl)phenyl)thieno[2,3-*b*]pyridine-2-carboxamide (7).**
15

16 Synthesized using a similar procedure used to prepare **1** except using **33d**. Crude was purified by silica
17 gel chromatography (hexanes/EtOAc) to give **7** (28 mg, 23%) as a light yellow solid. Purity 97%. ¹H
18 NMR (400 MHz, DMSO-*d*₆) δ 9.72 (s, 1H), 8.40 (d, *J* = 8.3 Hz, 1H), 7.96 (d, *J* = 8.5 Hz, 2H), 7.67 (d, *J* =
19 8.6 Hz, 2H), 7.47 (s, 2H), 7.35 (d, *J* = 8.3 Hz, 1H), 2.60 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ
20 164.23, 159.94, 158.57, 147.91, 142.90, 131.14, 125.62 (q, *J* = 3.5 Hz), 123.55, 123.21, 120.48,
21 119.61, 94.91, 24.27. ESI HRMS: 352.07336 (M+H)⁺.
22
23
24
25
26
27
28
29

30 **3-Amino-6-methyl-*N*-(2-(trifluoromethyl)phenyl)thieno[2,3-*b*]pyridine-2-carboxamide (8).**
31

32 Synthesized using a similar procedure used to prepare **1** except using **33e**. Crude was purified by silica
33 gel chromatography (hexanes/EtOAc) to give **8** (32 mg, 38%) as a light yellow solid. Purity 96%. ¹H
34 NMR (500 MHz, DMSO-*d*₆) δ 9.20 (s, 1H), 8.36 (d, *J* = 8.3 Hz, 1H), 7.77 (d, *J* = 7.8 Hz, 1H), 7.71 (t, *J* =
35 8.0 Hz, 1H), 7.57 (d, *J* = 7.9 Hz, 1H), 7.50 (t, *J* = 7.6 Hz, 1H), 7.34 (d, *J* = 8.3 Hz, 1H), 7.26 (s, 2H),
36 2.60 (s, 3H). ¹³C NMR (125 MHz, DMSO-*d*₆) δ 164.60, 159.64, 158.42, 146.95, 135.82, 132.89, 131.09,
37 130.77, 126.92, 126.40 (q, *J* = 4.9 Hz), 125.90 (q, *J* = 29.2 Hz), 123.74, 123.71 (q, *J* = 273.3 Hz),
38 119.56, 95.28, 24.29. ESI HRMS: 352.07291 (M+H)⁺.
39
40
41
42
43
44
45
46

47 **3-Amino-6-methyl-*N*-(3-(trifluoromethyl)benzyl)thieno[2,3-*b*]pyridine-2-carboxamide (9).**
48

49 Synthesized using a similar procedure used to prepare **1** except using **33f**. Crude was purified by silica
50 gel chromatography (hexanes/EtOAc) to give **9** (106 mg, 60%) as a light yellow solid. Purity 100%. ¹H
51 NMR (500 MHz, DMSO-*d*₆) δ 8.35 – 8.30 (m, 2H), 7.66 (s, 1H), 7.64 – 7.62 (m, 1H), 7.61 – 7.55 (m,
52 2H), 7.31 (d, *J* = 8.3 Hz, 1H), 7.18 (s, 2H), 4.48 (d, *J* = 5.9 Hz, 2H), 2.58 (s, 3H). ¹³C NMR (125 MHz,
53 DMSO-*d*₆) δ 165.27, 159.50, 158.22, 145.89, 141.75, 131.65, 131.07, 129.53, 129.11 (q, *J* = 31.5 Hz),
54
55
56
57
58
59
60

124.47 (q, $J = 272.2$ Hz), 124.06, 123.90 (q, $J = 3.7$ Hz), 123.63 (q, $J = 3.8$ Hz), 119.69, 95.79, 42.03, 24.35. ESI HRMS: 366.08889 (M+H)⁺.

3-Amino-6-isopropyl-*N*-(3-(trifluoromethyl)phenyl)thieno[2,3-*b*]pyridine-2-carboxamide (10).

Synthesized using a similar procedure used to prepare **1** except using **31c**. Crude was purified by flash column chromatography (hexanes/EtOAc) on silica gel to give **10** (44 mg, 78%) as a light yellow oil which solidified upon standing. Purity 93%. ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.68 (s, 1H), 8.44 (d, $J = 8.4$ Hz, 1H), 8.22 (s, 1H), 7.99 (d, $J = 8.2$ Hz, 1H), 7.56 (t, $J = 7.9$ Hz, 1H), 7.47 (s, 2H), 7.43 – 7.38 (m, 2H), 3.15 (p, $J = 6.9$ Hz, 1H), 1.29 (d, $J = 6.9$ Hz, 6H). ¹³C NMR (125 MHz, DMSO-*d*₆) δ 168.50, 164.23, 158.51, 147.78, 139.97, 131.47, 129.58, 129.15 (q, $J = 31.7$ Hz), 124.27, 124.23 (q, $J = 272.8$ Hz), 124.03, 119.43 (q, $J = 3.8$ Hz), 117.37, 116.86 (q, $J = 4.0$ Hz), 94.92, 39.85, 35.91, 22.41. ESI HRMS: 380.10396 (M+H)⁺.

6-Methyl-*N*-(3-(trifluoromethyl)phenyl)thieno[2,3-*b*]pyridine-2-carboxamide (11).

Synthesized using reported procedure with modification.²⁵ To a solution of **1** (56 mg, 0.16 mmol) in MeOH (6 mL) was added a solution of 50% H₃PO₂ (259 μL, 2.4 mmol) at 0 °C. To the reaction mixture was added conc. H₂SO₄ (655 μL), Cu₂O (14 mg, 0.10 mmol), 1 M NaNO₂ aqueous solution (239 μL) and the reaction mixture was stirred for 30 min at 0 °C. After stirring for 2 h and 30 min at room temperature, the reaction mixture was diluted with H₂O (30 mL) and the aqueous layer was extracted with EtOAc (20 mL x 2). The combined organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated *in vacuo*. Crude was purified by flash column chromatography (hexanes/EtOAc) on silica gel to give **11** (12 mg, 22%) as a white solid. Purity 98%. ¹H NMR (500 MHz, DMSO-*d*₆) δ 10.83 (s, 1H), 8.36 – 8.32 (m, 2H), 8.21 (s, 1H), 8.05 (d, $J = 8.2$ Hz, 1H), 7.63 (t, $J = 8.0$ Hz, 1H), 7.49 (d, $J = 7.8$ Hz, 1H), 7.41 (d, $J = 8.2$ Hz, 1H), 2.63 (s, 3H). ¹³C NMR (125 MHz, DMSO-*d*₆) δ 161.21, 160.54, 158.36, 139.31, 137.39, 133.71, 130.21, 130.09, 129.46 (q, $J = 31.7$ Hz), 124.53, 124.09 (q, $J = 272.3$ Hz), 123.78, 120.96, 120.34 (q, $J = 3.7$ Hz), 116.35 (q, $J = 4.0$ Hz), 24.29. ESI HRMS: 337.06096 (M+H)⁺.

7-Methyl-3-(3-(trifluoromethyl)phenyl)pyrido[3',2':4,5]thieno[3,2-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (12).

Synthesized using reported procedure with modification.²⁶ Triphosgene (13 mg, 0.043 mmol) was added to a stirred solution of **1** (30 mg, 0.084 mmol) in THF (2.5 mL) at room temperature. The

1
2 resulting mixture was heated under reflux for 1 h. The mixture was then cooled to room temperature
3
4 and diluted with THF (5 mL). The solid was collected by filtration and rinsed with cold THF to give a
5
6 white solid (28 mg, 90%). Purity 98%. ¹H NMR (500 MHz, DMSO-*d*₆) δ 12.81 (s, 1H), 8.65 (d, *J* = 8.4
7
8 Hz, 1H), 7.87 (s, 1H), 7.83 (d, *J* = 7.4 Hz, 1H), 7.78 – 7.72 (m, 2H), 7.55 (d, *J* = 8.4 Hz, 1H), 2.67 (s,
9
10 3H). ¹³C NMR (125 MHz, DMSO-*d*₆) δ 161.09, 160.73, 159.08, 151.33, 138.79, 136.39, 133.62, 131.96,
11
12 130.16, 129.73 (q, *J* = 32.1 Hz), 126.28 (q, *J* = 3.9 Hz), 125.24 (q, *J* = 3.7 Hz), 124.98, 122.82, 121.07,
13
14 120.37, 107.68, 24.46.. ESI HRMS: 378.05243 (M+H)⁺.

17 Representative procedure for thienopyridine sulfonamide preparation

18 **3-Amino-6-methyl-*N*-(3-(trifluoromethyl)phenyl)thieno[2,3-*b*]pyridine-2-sulfonamide (13).**

19 Synthesized using reported procedure with modification.²⁷ To a solution of **25** (32 mg, 0.21 mmol) in
20
21 anhydrous DMF (1.5 mL) was added **35** (63 mg, 0.22 mmol) and sodium ethoxide (33 mg, 0.46 mmol).
22
23 The mixture was heated to 130 °C for 1 h. The mixture was diluted with H₂O (10 mL) and extracted with
24
25 EtOAc (10 mL x 2) and finally washed with brine (10 mL). The organic layer was dried (Na₂SO₄),
26
27 filtered, and concentrated *in vacuo*. Crude was purified by silica gel chromatography (hexanes/EtOAc)
28
29 to give **13** (27 mg, 33%) as a light yellow solid. Purity 96%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.75 (s,
30
31 1H), 8.35 (d, *J* = 8.3 Hz, 1H), 7.49 (t, *J* = 7.9 Hz, 1H), 7.45 – 7.38 (m, 2H), 7.37 – 7.30 (m, 2H), 6.83 (s,
32
33 2H), 2.55 (s, 3H). ¹³C NMR (126 MHz, DMSO) δ 160.74, 158.96, 144.69, 139.28, 132.25, 130.93,
34
35 130.25 (q, *J* = 31.5 Hz), 125.34, 123.57, 123.16, 120.51, 115.43, 97.64, 24.68. ESI HRMS: 388.04044
36
37 (M+H)⁺.

38
39
40
41
42
43 **3-Amino-*N*-(3-fluorophenyl)-6-methylthieno[2,3-*b*]pyridine-2-sulfonamide (14).** Synthesized using
44
45 a similar procedure used to prepare **13** except using **36**. Crude was purified by silica gel
46
47 chromatography (hexanes/EtOAc) to give **14** (96 mg, 72%) as an oil which was solidified to a beige
48
49 solid upon standing. Purity 100%. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.60 (s, 1H), 8.33 (d, *J* = 8.3 Hz,
50
51 1H), 7.33 (d, *J* = 8.4 Hz, 1H), 7.26 (td, *J* = 8.4, 6.9 Hz, 1H), 6.97 – 6.88 (m, 2H), 6.85 – 6.80 (m, 1H),
52
53 6.80 – 6.76 (m, 2H), 2.54 (s, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 162.21 (d, *J* = 242.8 Hz), 160.13,
54
55 158.48, 143.89, 139.73 (d, *J* = 10.7 Hz), 131.72, 130.82 (d, *J* = 9.5 Hz), 123.13, 119.98, 114.88 (d, *J* =
56
57 2.7 Hz), 110.08 (d, *J* = 21.0 Hz), 105.70 (d, *J* = 25.4 Hz), 97.72, 24.17. ESI HRMS: 338.04340 (M+H)⁺.

Representative procedure for oxadiazolyl thienopyridine preparation**6-Methyl-2-(5-(3-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thieno[2,3-*b*]pyridin-3-amine (15).**

To a stirring solution of **25** (42 mg, 0.28 mmol) in anhydrous DMF (2 mL) was added commercially available 5-(chloromethyl)-3-[3-(trifluoromethyl)phenyl]-1,3,4-oxadiazole, **37l**, (66 mg, 0.24 mmol) and sodium ethoxide (50 mg, 0.63 mmol). The mixture was heated to 130 °C for 1 h. The mixture was then cooled to room temperature and solid precipitated at the bottom of the flask. The solid was collected by filtration and rinsed with cold MeOH and dried *in vacuo* to give a yellow solid (28 mg, 31% yield). Purity 96%. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.50 (d, *J* = 8.3 Hz, 1H), 8.40 (d, *J* = 7.9 Hz, 1H), 8.35 (s, 1H), 8.01 (d, *J* = 7.9 Hz, 1H), 7.87 (t, *J* = 7.8 Hz, 1H), 7.39 (d, *J* = 8.3 Hz, 1H), 7.26 (s, 2H), 2.61 (s, 3H). ¹³C NMR (125 MHz, DMSO-*d*₆) δ 162.36, 160.47, 159.33, 159.28, 143.73, 131.25, 130.80, 130.50, 130.18, 129.92, 128.06 (q, *J* = 3.3 Hz), 124.80, 124.45, 123.38, 122.77 (q, *J* = 3.7 Hz), 122.63, 119.88, 85.96, 24.21. ESI HRMS: 377.06832 (M+H)⁺.

6-Methyl-2-(3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)thieno[2,3-*b*]pyridin-3-amine (16).

Synthesized using a similar procedure used to prepare **15** except using commercially available 5-(chloromethyl)-3-[3-(trifluoromethyl)phenyl]-1,3,4-oxadiazole, **37m**. Precipitated solid was filtered, rinsed with cold MeOH, and dried *in vacuo* to give the title compound (31 mg, 67% yield) as a red solid. Purity 99%. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.55 (d, *J* = 8.3 Hz, 1H), 8.48 (d, *J* = 7.7 Hz, 1H), 8.43 (s, 1H), 8.00 (d, *J* = 7.6 Hz, 1H), 7.84 (t, *J* = 7.7 Hz, 1H), 7.63 (s, 2H), 7.41 (d, *J* = 8.3 Hz, 1H), 2.61 (s, 3H). ¹³C NMR (125 MHz, DMSO-*d*₆) δ 172.46, 166.38, 160.44, 159.78, 146.38, 131.88, 131.35, 130.51, 129.92 (q, *J* = 32.1 Hz), 128.09 (d, *J* = 3.3 Hz), 127.46, 123.64 (q, *J* = 3.7 Hz), 122.93, 122.76 (q, *J* = 272 Hz), 119.99, 85.79, 24.28. ESI HRMS: 377.06809 (M+H)⁺.

6-Methyl-2-(5-phenyl-1,3,4-oxadiazol-2-yl)thieno[2,3-*b*]pyridin-3-amine (17).

Synthesized using a similar procedure used to prepare **15** except using **25** and commercially available 2-(chloromethyl)-5-phenyl-1,3,4-oxadiazole, **37n**. Precipitated solid was filtered, rinsed with cold MeOH, and dried *in vacuo* to give the title compound (24 mg, 65% yield) as a yellow solid. Purity 96%. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.46 (d, *J* = 8.3 Hz, 1H), 8.11 – 8.08 (m, 2H), 7.65 – 7.61 (m, 3H), 7.40 (d, *J* = 8.3 Hz, 1H), 7.18 (s,

2H), 2.61 (s, 3H). ^{13}C NMR (125 MHz, DMSO- d_6) δ 161.93, 161.45, 159.19, 159.17, 143.37, 131.70, 131.12, 129.41, 126.50, 123.40, 123.28, 119.87, 86.23, 24.21. ESI HRMS: 309.08079 (M+H) $^+$.

2-(5-(3-Chlorophenyl)-1,3,4-oxadiazol-2-yl)-6-methylthieno[2,3-*b*]pyridin-3-amine (18).

Synthesized using a similar procedure used to prepare **15** except using **25** and commercially available 2-(chloromethyl)-5-(3-chlorophenyl)-1,3,4-oxadiazole, **37o**. Precipitated solid was filtered, rinsed with cold MeOH, and dried *in vacuo* to give the title compound (26 mg, 42% yield) as a yellow solid. Purity 96%. ^1H NMR (500 MHz, DMSO- d_6) δ 8.46 (d, J = 8.3 Hz, 1H), 8.11 (t, J = 1.7 Hz, 1H), 8.06 (dt, J = 7.6, 1.2 Hz, 1H), 7.70 (ddd, J = 8.1, 2.0, 1.1 Hz, 1H), 7.65 (t, J = 7.9 Hz, 1H), 7.39 (d, J = 8.3 Hz, 1H), 7.20 (s, 2H), 2.61 (s, 3H). ^{13}C NMR (125 MHz, DMSO- d_6) δ 162.22, 160.43, 159.29, 159.27, 143.58, 134.03, 131.44, 131.41, 131.16, 125.93, 125.25, 125.20, 123.38, 119.87, 86.08, 24.21. ESI HRMS: 343.04216 (M+H) $^+$.

2-(5-(3-(Trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)thieno[2,3-*b*]pyridin-3-amine (19).

Synthesized using a similar procedure used to prepare **15** except using commercially available 2-Mercaptopyridine-3-carbonitrile, **38**, and **37m**. Precipitated solid was filtered, rinsed with cold MeOH, and dried *in vacuo* to give the title compound (55 mg, 76% yield) as a yellow solid. Purity 99%. ^1H NMR (500 MHz, DMSO- d_6) δ 8.69 (dd, J = 4.6, 1.6 Hz, 1H), 8.61 (dd, J = 8.2, 1.6 Hz, 1H), 8.41 (d, J = 7.9 Hz, 1H), 8.36 (s, 1H), 8.02 (d, J = 7.9 Hz, 1H), 7.88 (t, J = 7.8 Hz, 1H), 7.54 (dd, J = 8.1, 4.6 Hz, 1H), 7.29 (s, 2H). ^{13}C NMR (125 MHz, DMSO- d_6) δ 162.22, 160.66, 159.56, 149.93, 143.49, 131.17, 130.80, 130.55, 129.94 (q, J = 32 Hz), 128.14 (q, J = 3.3 Hz), 125.69, 124.79, 124.41, 122.84 (q, J = 3.9 Hz), 122.62, 119.86, 87.02. ESI HRMS: 363.05232 (M+H) $^+$.

Representative procedure for 2-mercaptopyridine preparation

2-Mercapto-6-methylnicotinonitrile (25). Synthesized using reported procedure with modification.²⁰ A mixture of 2-chloro-6-methylnicotinonitrile, **24**, (222 mg, 1.44 mmol) and thiourea (348 mg, 4.57 mmol) was heated at reflux (118 °C) in n-butanol for 3 h. A yellow suspension was obtained. After cooling to room temperature, the yellow solid was precipitated. The solids were collected by filtration, rinsed with cold n-butanol, and dried *in vacuo* to give the title compound (217 mg, quantitative) as a light yellow solid. ^1H NMR (500 MHz, DMSO- d_6) δ 14.07 (s, 1H), 7.99 (d, J = 7.7 Hz, 1H), 6.73 (d, J = 7.7 Hz, 1H),

2.39 (s, 3H). ^{13}C NMR (125 MHz, $\text{DMSO-}d_6$) δ 177.70, 155.00, 145.03, 117.20, 113.40, 112.75, 19.14.

ESI MS: m/z 149.1 (M-H) $^-$.

Representative procedure for acetamide preparation

2-Bromo-*N*-(3-(trifluoromethyl)phenyl)acetamide (27). Synthesized using reported procedure with modification.²¹ A stirred solution of 3-(trifluoromethyl)aniline, **26**, (170 μL , 1.36 mmol) and 4-(dimethylamino)pyridine (70 mg, 42 mol%) in CH_2Cl_2 (8 mL) was treated dropwise with bromoacetyl bromide (140 μL , 1.61 mmol) at 0 $^\circ\text{C}$. The reaction mixture was allowed to warm up to room temperature with good stirring overnight. The mixture was diluted with H_2O (30 mL) and extracted with EtOAc (20 mL x 2). The organic layer was dried (MgSO_4), filtered, and concentrated *in vacuo*. Crude was purified by flash column chromatography (hexanes/EtOAc) on silica gel to give **27** (339 mg, 88%) as a light brown oil which solidified upon standing. ^1H NMR (500 MHz, CDCl_3) δ 8.23 (s, 1H), 7.83 (s, 1H), 7.75 (d, J = 8.1 Hz, 1H), 7.49 (t, J = 7.9 Hz, 1H), 7.45 – 7.41 (m, 1H), 4.05 (s, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 163.70, 137.55, 131.74 (q, J = 32.7 Hz), 129.87, 123.83 (q, J = 272.4 Hz), 123.18, 121.95 (q, J = 3.8 Hz), 116.88 (q, J = 3.9 Hz), 29.40. ESI MS: m/z 281.55, 283.50 (M+H) $^+$.

Representative procedure for pyridinium acetamido bromide preparation

4-(2-Bromoacetamido)pyridin-1-ium bromide (29g). Synthesized using reported procedure with modification.²³ To a stirred solution of 4-aminopyridine, **28g**, (201 mg, 2.14 mmol) in dry CH_2Cl_2 (5 mL) at 0 $^\circ\text{C}$ was added bromoacetyl bromide (195 μL , 2.24 mmol) dropwise. As soon as bromoacetyl bromide was added, the reaction mixture turned cloudy and a white precipitate formed. The mixture was allowed to warm to room temperature with good stirring overnight. Mixture was filtered and the solid was washed with cold CH_2Cl_2 to give **29g** as a white solid which was used in the next step without further purification. ESI MS: m/z 214.45, 216.45 (M+H) $^+$.

3-(2-Bromoacetamido)pyridin-1-ium bromide (29h). Synthesized using a similar procedure used to prepare **29g** using 3-aminopyridine, **28h**. The mixture was allowed to warm to room temperature with good stirring over 3 h. Mixture was filtered and the solid was washed with cold CH_2Cl_2 to give the title compound (609 mg, 95%) as a beige solid which was used in the next step without further purification. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 11.42 (s, 1H), 9.20 (d, J = 2.3 Hz, 1H), 8.65 (d, J = 5.4 Hz, 1H), 8.50

(d, $J = 8.6$ Hz, 1H), 7.99 (dd, $J = 8.5, 5.5$ Hz, 1H), 4.19 (s, 2H). ^{13}C NMR (100 MHz, $\text{DMSO-}d_6$) δ 166.22, 137.81, 137.58, 134.35, 132.52, 127.48, 29.53. ESI MS: m/z 214.45, 216.40 ($\text{M}+\text{H}$) $^+$.

2-Bromo-*N*-(pyridin-2-yl)acetamide hydrobromide (29i). Synthesized using a similar procedure used to prepare **29g** except using 2-aminopyridine, **28i**. The mixture was allowed to warm to room temperature with good stirring over 3 h. Mixture was filtered and the solid was washed with cold CH_2Cl_2 to give the title compound (342 mg, 55%) as a light purple solid which was used in the next step without further purification. ^1H NMR (500 MHz, CDCl_3) δ 8.81 (s, 1H), 8.32 (d, $J = 3.7$ Hz, 1H), 8.17 (s, 1H), 7.74 (t, $J = 7.6$ Hz, 1H), 7.13 – 7.06 (m, 1H), 4.01 (s, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 164.23, 150.72, 148.15, 138.66, 120.72, 114.02, 29.20. ESI MS: m/z 214.45, 216.45 ($\text{M}+\text{H}$) $^+$.

2-Mercapto-4-methylnicotinonitrile (31a). Synthesized using a similar procedure used to prepare **25** except using 2-chloro-4-methylnicotinonitrile, **30a**. Precipitated solid was filtered, rinsed with cold *n*-butanol, and dried *in vacuo* to give the title compound (237 mg, quantitative) as a light yellow solid. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 7.81 (d, $J = 6.4$ Hz, 1H), 6.82 (d, $J = 6.4$ Hz, 1H), 2.40 (s, 3H). ^{13}C NMR (100 MHz, $\text{DMSO-}d_6$) δ 177.05, 157.57, 140.65, 116.31, 115.93, 114.61, 20.99. ESI MS: m/z 149.1 ($\text{M}-\text{H}$) $^-$.

2-Mercapto-5-methylnicotinonitrile (31b). Synthesized using a similar procedure used to prepare **25** except using 2-chloro-5-methylnicotinonitrile, **30b**. Precipitated solid was filtered, rinsed with cold *n*-butanol, and dried *in vacuo* to give the title compound (121 mg, quantitative) as a light yellow solid. ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 14.10 (s, 1H), 8.04 (d, $J = 1.9$ Hz, 1H), 7.83 (s, 1H), 2.10 (s, 3H). ^{13}C NMR (126 MHz, DMSO) δ 174.77, 147.03, 141.45, 122.24, 116.90, 116.08, 16.06. ESI MS: m/z 149.1 ($\text{M}-\text{H}$) $^-$.

6-Isopropyl-2-mercaptonicotinonitrile (31c). Synthesized using reported procedure with modification.²⁴ A suspension of 2-chloro-6-isopropylnicotinonitrile, **30c**, (53 mg, 0.29 mmol) and Lawesson's reagent (135 mg, >90% purity, 0.30 mmol) in toluene (2.5 mL) was refluxed at 110 °C for 4 h 30 min. The reaction mixture was cooled down to room temperature and filtered through a Celite plug to remove any unreacted Lawesson's reagent. The solvent was evaporated and crude was purified by silica gel chromatography (hexanes/EtOAc) to give **31c** (22 mg, 42% yield) as a yellow sticky solid. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 14.04 (s, 1H), 8.04 (d, $J = 7.8$ Hz, 1H), 6.78 (d, $J = 7.8$ Hz, 1H), 3.06 (p, J

= 6.9 Hz, 1H), 1.20 (d, J = 6.9 Hz, 6H). ^{13}C NMR (100 MHz, $\text{DMSO-}d_6$) δ 177.78, 163.81, 145.44, 117.06, 113.98, 109.04, 31.42, 21.17. ESI MS: m/z 179.1 ($\text{M}+\text{H}$) $^+$, 177.1 ($\text{M}-\text{H}$) $^-$.

2-Bromo-*N*-(4-(trifluoromethyl)phenyl)acetamide (33d). Synthesized using a similar procedure used to prepare **27** except using 4-(trifluoromethyl)aniline, **32d**. The reaction mixture was allowed to warm up to room temperature with good stirring over 8 h. The mixture was diluted with H_2O (30 mL) and extracted with EtOAc (20 mL x 2). The organic layer was dried (MgSO_4), filtered, and concentrated *in vacuo*. Crude (355 mg, 94%), a white solid, was used in the next step without further purification. ^1H NMR (500 MHz, CDCl_3) δ 8.24 (s, 1H), 7.68 (d, J = 8.5 Hz, 2H), 7.62 (d, J = 8.5 Hz, 2H), 4.05 (s, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 163.69, 140.05, 127.18 (q, J = 33.0 Hz), 126.56 (q, J = 3.8 Hz), 124.04 (q, J = 271.8 Hz), 119.73, 29.44. ESI MS: m/z 281.50, 283.55 ($\text{M}+\text{H}$) $^+$.

2-Bromo-*N*-(2-(trifluoromethyl)phenyl)acetamide (33e). Synthesized using a similar procedure used to prepare **27** except using 2-(trifluoromethyl)aniline, **32e**, and letting the reaction to stir overnight at room temperature. Crude (397 mg, 89%), a beige solid, was used in the next step without further purification. ^1H NMR (500 MHz, CDCl_3) δ 8.60 (s, 1H), 8.19 (d, J = 8.3 Hz, 1H), 7.65 (d, J = 7.9 Hz, 1H), 7.59 (t, J = 7.9 Hz, 1H), 7.29 (t, J = 7.7 Hz, 1H), 4.07 (s, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 163.89, 134.59, 133.11, 126.38 (q, J = 5.3 Hz), 125.40, 124.17, 123.98 (q, J = 273.1 Hz), 120.79 (q, J = 29.9 Hz), 29.43. ESI MS: m/z 281.50, 283.50 ($\text{M}+\text{H}$) $^+$.

2-Bromo-*N*-(3-(trifluoromethyl)benzyl)acetamide (33f). Synthesized using a similar procedure used to prepare **27** except using 3-(trifluoromethyl)benzylamine, **32f**, and letting the reaction to stir for 6h at room temperature. Crude was purified by silica gel chromatography (hexanes/EtOAc) to give **33f** (316 mg, 62%) as a white solid. ^1H NMR (500 MHz, CDCl_3) δ 7.58 – 7.55 (m, 1H), 7.54 (s, 1H), 7.51 – 7.45 (m, 2H), 6.85 (s, 1H), 4.54 (d, J = 6.0 Hz, 2H). ^{13}C NMR (125 MHz, CDCl_3) δ 165.68, 138.54, 131.31 (q, J = 33.5 Hz), 131.18, 129.49, 124.79, 124.54, 124.06 (q, J = 272.1 Hz), 43.80, 29.16. ESI MS: m/z 295.50, 297.55 ($\text{M}+\text{H}$) $^+$.

Representative procedure for chloromethanesulfonamide preparation

1-Chloro-*N*-(3-(trifluoromethyl)phenyl)methanesulfonamide (35). Synthesized using reported procedure with modification.²⁷ To a stirring solution of 3-(trifluoromethyl)aniline, **26**, (388 μL , 3.11 mmol)

1
2 in CH₂Cl₂ (6 mL) was added Et₃N (865 μL, 6.20 mmol) at room temperature. The reaction mixture was
3
4 cool down to 0 °C and chloromethanesulfonyl chloride (626 μL, 6.20 mmol) in CH₂Cl₂ (3 mL) was added
5
6 at 0 °C. The reaction mixture was stirred at room temperature overnight. The reaction mixture was
7
8 concentrated on vacuo then 2 N NaOH (15 mL) was added and the mixture was stirred at room
9
10 temperature for 2 h 30 min. The reaction mixture was neutralized by 1N HCl. The mixture was diluted
11
12 with H₂O (10 mL) and extracted with EtOAc (20 mL x 2) and finally washed with brine (10 mL). The
13
14 organic layer was dried (Na₂SO₄), filtered, and concentrated *in vacuo*. Crude was purified by silica gel
15
16 chromatography (hexanes/EtOAc) to give **35** (614 mg, 72%) as a beige solid. ¹H NMR (400 MHz,
17
18 DMSO-*d*₆) δ 10.77 (s, 1H), 7.62 – 7.56 (m, 1H), 7.56 – 7.51 (m, 2H), 7.49 (d, *J* = 7.6 Hz, 1H), 5.13 (s,
19
20 2H). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 138.25, 130.64, 129.96 (q, *J* = 31.8 Hz), 125.17, 123.64, 122.46,
21
22 120.71 (q, *J* = 3.6 Hz), 116.08 (q, *J* = 4.1 Hz), 54.87. ESI MS: *m/z* 272.0 (M-H)⁻.

23
24
25 **1-Chloro-*N*-(3-fluorophenyl)methanesulfonamide (36)**. Synthesized using a similar procedure used
26
27 to prepare **35** except using 3-fluoroaniline, **34**. Crude was purified by silica gel column chromatography
28
29 (hexanes/EtOAc) to give **36** (347 mg, 60%) as a yellow oil which was solidified upon standing. ¹H NMR
30
31 (400 MHz, CDCl₃) δ 7.35 (td, *J* = 8.2, 6.3 Hz, 1H), 7.11 – 7.03 (m, 2H), 6.97 (tdd, *J* = 8.3, 2.4, 0.8 Hz,
32
33 1H), 6.90 (s, 1H), 4.51 (s, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 163.33 (d, *J* = 248.3 Hz), 136.96 (d, *J* =
34
35 10.2 Hz), 131.22 (d, *J* = 9.3 Hz), 117.68 (d, *J* = 3.2 Hz), 113.62 (d, *J* = 21.2 Hz), 109.71 (d, *J* = 25.2
36
37 Hz), 53.58. ESI MS: *m/z* 222.00 (M-H)⁻.

38 39 40 41 42 43 **Supporting Information**

44
45 Molecular formula strings and associated biochemical data, procedure for the synthesis of **20-26** and
46
47 biochemical data, ligand-detected full ¹H NMR spectra of **2** and **14**, full TOCSY spectra of free TAR and
48
49 in presence of different concentration of **2**, ¹H NMR and ¹³C NMR spectra for all compounds.

50 51 52 53 54 **Corresponding Author**

55
56 *Phone: +1 301-228-4620. Email:schneeklothjs@mail.nih.gov

57
58 Notes

1
2 The authors declare no competing financial interest.
3
4
5

6 **Acknowledgements**

7
8 This work was supported by the Intramural Research Program of the National Institutes of Health,
9
10 Center for Cancer Research, the National Cancer Institute (NCI), and the IATAP program, National
11
12 Institutes of Health. Work at the University of Washington was supported by NIH-NIGMS GM110569.
13
14 M. Shortridge was supported by an American Cancer Society fellowship (PF-13-056-01-RMC). We
15
16 thank the Biophysics Resource in the Structural Biophysics Laboratory, NCI at Frederick for assistance
17
18 with Q-TOF LC-MS studies.
19

20 **Abbreviations Used**

21
22
23 TAR, transactivation response element; 5'-UTR, 5'-untranslated region; SMM, small molecule
24
25 microarray; 2AP, 2-aminopurine; FRET, Forster resonance energy transfer; SHAPE, selective 2'-
26
27 hydroxyl acylation analyzed by primer extension. Solvent and reagent abbreviation used: 1M7, 1-
28
29 methyl-7-nitroisatoic anhydride; MgCl₂, magnesium chloride; ACN, acetonitrile; MeOH, methanol;
30
31 EtOH, ethanol; EtOAc, ethylacetate; Na₂SO₄, sodium sulfate; NaOEt, sodium ethoxide; H₂SO₄, sulfuric
32
33 acid; H₃PO₂, hypophosphorous acid; NaNO₂, sodium nitrite; Cu₂O, copper (I) oxide; Et₃N,
34
35 trimethylamine.
36
37

38 **References**

- 39
40
41 1. Shortridge, M. D.; Varani, G. Structure based approaches for targeting non-coding RNAs with
42
43 small molecules. *Curr. Opin. Struct. Biol.* **2015**, *30*, 79-88.
44
45 2. Dingwall, C.; Ernberg, I.; Gait, M. J.; Green, S. M.; Heaphy, S.; Karn, J.; Lowe, A. D.; Singh, M.;
46
47 Skinner, M. A.; Valerio, R. Human immunodeficiency virus-1 Tat protein binds trans-activation-
48
49 responsive region (TAR) RNA in vitro. *Proc. Natl. Acad. Sci. U.S.A.* **1989**, *86* (18), 6925-6929.
50
51 3. Dingwall, C.; Ernberg, I.; Gait, M. J.; Green, S. M.; Heaphy, S.; Karn, J.; Lowe, A. D.; Singh, M.;
52
53 Skinner, M. A. HIV-1 Tat protein stimulates transcription by binding to a U-rich bulge in the stem of the
54
55 TAR RNA structure. *EMBO J.* **1990**, *9* (12), 4145-4153.
56
57 4. Berkhout, B.; Jeang, K. T. Trans activation of human immunodeficiency virus type 1 is sequence
58
59 specific for both the single-stranded bulge and loop of the trans-acting-responsive hairpin: a
60
quantitative analysis. *J. Virol.* **1989**, *63* (12), 5501-5504.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
5. Berkhout, B.; Silverman, R. H.; Jeang, K. T. Tat trans-activates the human immunodeficiency virus through a nascent RNA target. *Cell* **1989**, *59* (2), 273-282.
6. Berkhout, B. Structural features in TAR RNA of human and simian immunodeficiency viruses: a phylogenetic analysis. *Nucleic Acids Res.* **1992**, *20* (1), 27-31.
7. Huthoff, H.; Girard, F.; Wijmenga, S. S.; Berkhout, B. Evidence for a base triple in the free HIV-1 TAR RNA. *RNA* **2004**, *10* (3), 412-423.
8. Harrich, D.; Ulich, C.; Gaynor, R. B. A critical role for the TAR element in promoting efficient human immunodeficiency virus type 1 reverse transcription. *J. Virol.* **1996**, *70* (6), 4017-4027.
9. Harrich, D.; Ulich, C.; Garcia-Martinez, L. F.; Gaynor, R. B. Tat is required for efficient HIV-1 reverse transcription. *EMBO J.* **1997**, *16* (6), 1224-1235.
10. Lalonde, M. S.; Lobritz, M. A.; Ratcliff, A.; Chamanian, M.; Athanassiou, Z.; Tyagi, M.; Wong, J.; Robinson, J. A.; Karn, J.; Varani, G.; Arts, E. J. Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA. *PLoS Pathog.* **2011**, *7* (5), e1002038.
11. Klase, Z.; Kale, P.; Winograd, R.; Gupta, M. V.; Heydarian, M.; Berro, R.; McCaffrey, T.; Kashanchi, F. HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR. *BMC Mol. Biol.* **2007**, *8*, 63.
12. Klase, Z.; Winograd, R.; Davis, J.; Carpio, L.; Hildreth, R.; Heydarian, M.; Fu, S.; McCaffrey, T.; Meiri, E.; Ayash-Rashkovsky, M.; Gilad, S.; Bentwich, Z.; Kashanchi, F. HIV-1 TAR miRNA protects against apoptosis by altering cellular gene expression. *Retrovirology* **2009**, *6*, 18.
13. Ouellet, D. L.; Vigneault-Edwards, J.; Letourneau, K.; Gobeil, L. A.; Plante, I.; Burnett, J. C.; Rossi, J. J.; Provost, P. Regulation of host gene expression by HIV-1 TAR microRNAs. *Retrovirology* **2013**, *10*, 86.
14. Le Grice, S. F. J. Targeting the HIV RNA genome: high-hanging fruit only needs a longer ladder. In *future of HIV-1 therapeutics: resistance is futile?*, Torbett, B. E.; Goodsell, D. S.; Richman, D. D., Eds. Springer International Publishing: Cham, Switzerland, 2015; Vol. 389, pp 147-169.
15. Thomas, J. R.; Hergenrother, P. J. Targeting RNA with small molecules. *Chem. Rev.* **2008**, *108* (4), 1171-1224.
16. Guan, L. R.; Disney, M. D. Recent advances in developing small molecules targeting RNA. *ACS Chem. Biol.* **2012**, *7* (1), 73-86.

- 1
2 17. Blond, A.; Ennifar, E.; Tisne, C.; Micouin, L. The design of RNA binders: targeting the HIV
3 replication cycle as a case study. *ChemMedChem* **2014**, *9* (9), 1982-1996.
4
5
6 18. Abulwerdi, F. A.; Schneekloth, J. S., Jr. Microarray-based technologies for the discovery of
7 selective, RNA-binding molecules. *Methods* **2016**, *103*, 188-195.
8
9
10 19. Sztuba-Solinska, J.; Shenoy, S. R.; Gareiss, P.; Krumpe, L. R. H.; Le Grice, S. F. J.; O'Keefe, B.
11 R.; Schneekloth, J. S. Identification of biologically active, HIV TAR RNA-binding small molecules using
12 small molecule microarrays. *J. Am. Chem. Soc.* **2014**, *136* (23), 8402-8410.
13
14
15 20. Chang, Z.; Hu, C.; Fang, J.; Yeh, M.; Zhang, Z.; Ye, M.; Chang, Z. F.; Fang, J. M.; Hu, C. M.;
16 Yeh, M. T. Composition for inhibiting thymidylate kinase and for sensitizing cancer cells to radiation
17 therapy, chemotherapy or immunomodulatory therapy, comprises benzo/pyrido-thiazolone or
18 phthalimide derivative. WO2012072019-A1, 2012.
19
20
21 21. Kirubakaran, S.; Gorla, S. K.; Sharling, L.; Zhang, M. J.; Liu, X. P.; Ray, S. S.; MacPherson, I.
22 S.; Striepen, B.; Hedstrom, L.; Cuny, G. D. Structure-activity relationship study of selective
23 benzimidazole-based inhibitors of *Cryptosporidium parvum* IMPDH. *Bioorg. Med. Chem. Lett.* **2012**, *22*
24 (5), 1985-1988.
25
26
27 22. Dai, D.; Burgeson, J. R.; Tyavanagimatt, S. R. B., Chelsea M. ; Hruby, D. E. Thienopyridine
28 derivatives for the treatment and prevention of dengue virus infections. 20130129677, 2013.
29
30
31 23. Xie, H.; Ng, D.; Savinov, S. N.; Dey, B.; Kwong, P. D.; Wyatt, R.; Smith, A. B.; Hendrickson, W.
32 A. Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human
33 immunodeficiency virus. *J. Med. Chem.* **2007**, *50* (20), 4898-4908.
34
35
36 24. Tseng, C. H.; Lin, R. W.; Chen, Y. L.; Wang, G. J.; Ho, M. L.; Tzeng, C. C. Discovery of
37 indeno[1,2-c]quinoline derivatives as inhibitors of osteoclastogenesis induced by receptor activator of
38 NF-kappa B ligand (RANKL). *J. Med. Chem.* **2011**, *54* (8), 3103-3107.
39
40
41 25. Suzuki, T.; Miyajima, Y.; Suzuki, K.; Iwakiri, K.; Koshimizu, M.; Hirai, G.; Sodeoka, M.;
42 Kobayashi, S. Unexpected diels-alder/carbonyl-ene cascade toward the biomimetic synthesis of
43 chloropupukeananin. *Org. Lett.* **2013**, *15* (7), 1748-1751.
44
45
46 26. Jiang, M.; Li, B. B. X.; Xie, F. C.; Delaney, F.; Xiao, X. S. Design, synthesis, and biological
47 evaluation of conformationally constrained analogues of naphthol AS-E as inhibitors of CREB-mediated
48 gene transcription. *J. Med. Chem.* **2012**, *55* (8), 4020-4024.
49
50
51 27. Nogradi, K.; Wagner, G.; Keserue, G.; Bielik, A.; Gati, T.; Hada, V.; Koti, J.; Gal, K.; Vastag, M.;
52 Bobok, A. A.; Bobok, A.; Wagner, G. A.; Keseru, G.; Keserli, G.; Krisztina, V. M. New substituted
53 thienopyridine compounds are metabotropic glutamate receptor 1 inhibitors, useful for treating e.g.
54 gastrointestinal reflux disease, irritable bowel syndrome, neuropathic pain and Alzheimer's disease.
55 WO2007072095-A1, 2007.
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
28. Zhang, M. Z.; Mulholland, N.; Beattie, D.; Irwin, D.; Gu, Y. C.; Chen, Q.; Yang, G. F.; Clough, J. Synthesis and antifungal activity of 3-(1,3,4-oxadiazol-5-yl)-indoles and 3-(1,3,4-oxadiazol-5-yl)methyl-indoles. *Eur. J. Med. Chem.* **2013**, *63*, 22-32.
29. Bradrick, T. D.; Marino, J. P. Ligand-induced changes in 2-aminopurine fluorescence as a probe for small molecule binding to HIV-1 TAR RNA. *RNA* **2004**, *10* (9), 1459-1468.
30. Bardaro, M. F., Jr.; Shajani, Z.; Patora-Komisarska, K.; Robinson, J. A.; Varani, G. How binding of small molecule and peptide ligands to HIV-1 TAR alters the RNA motional landscape. *Nucleic Acids Res.* **2009**, *37* (5), 1529-1540.
31. Stelzer, A. C.; Frank, A. T.; Kratz, J. D.; Swanson, M. D.; Gonzalez-Hernandez, M. J.; Lee, J.; Andricioaei, I.; Markovitz, D. M.; Al-Hashimi, H. M. Discovery of selective bioactive small molecules by targeting an RNA dynamic ensemble. *Nat. Chem. Biol.* **2011**, *7* (8), 553-559.
32. Matsumoto, C.; Hamasaki, K.; Mihara, H.; Ueno, A. A high-throughput screening utilizing intramolecular fluorescence resonance energy transfer for the discovery of the molecules that bind HIV-1 TAR RNA specifically. *Bioorg. Med. Chem. Lett.* **2000**, *10* (16), 1857-1861.
33. Pascale, L.; Azoulay, S.; Di Giorgio, A.; Zenacker, L.; Gaysinski, M.; Clayette, P.; Patino, N. Thermodynamic studies of a series of homologous HIV-1 TAR RNA ligands reveal that loose binders are stronger Tat competitors than tight ones. *Nucleic Acids Res.* **2013**, *41* (11), 5851-5863.
34. Shortridge, M. D.; Hage, D. S.; Harbison, G. S.; Powers, R. Estimating protein-ligand binding affinity using high-throughput screening by NMR. *J. Comb. Chem.* **2008**, *10* (6), 948-958.
35. Puglisi, J. D.; Tan, R. Y.; Calnan, B. J.; Frankel, A. D.; Williamson, J. R. Conformation of the TAR RNA-arginine complex by NMR-spectroscopy. *Science* **1992**, *257* (5066), 76-80.
36. Aboulela, F.; Karn, J.; Varani, G. The structure of the human-immunodeficiency-virus type-1 Tar RNA reveals principles of RNA recognition by Tat protein. *J. Mol. Biol.* **1995**, *253* (2), 313-332.
37. Hamy, F.; Brondani, V.; Florsheimer, A.; Stark, W.; Blommers, M. J. J.; Klimkait, T. A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition. *Biochemistry* **1998**, *37* (15), 5086-5095.
38. Faber, C.; Sticht, H.; Schweimer, K.; Rosch, P. Structural rearrangements of HIV-1 Tat-responsive RNA upon binding of neomycin B. *J. Biol. Chem.* **2000**, *275* (27), 20660-20666.
39. Dassonneville, L.; Hamy, F.; Colson, P.; Houssier, C.; Bailly, C. Binding of hoechst 33258 to the TAR RNA of HIV-1. recognition of a pyrimidine bulge-dependent structure. *Nucleic Acids Res.* **1997**, *25* (22), 4487-4492.

- 1
2 40. Wilkinson, K. A.; Gorelick, R. J.; Vasa, S. M.; Guex, N.; Rein, A.; Mathews, D. H.; Giddings, M.
3 C.; Weeks, K. M. High-throughput SHAPE analysis reveals structures in HIV-1 genomic RNA strongly
4 conserved across distinct biological states. *PLoS Biol.* **2008**, *6* (4), 883-899.
5
6
7 41. Krawczyk, K.; Sim, A. Y.; Knapp, B.; Deane, C. M.; Minary, P. Tertiary element interaction in
8 HIV-1 TAR. *J. Chem. Inf. Model.* **2016**, *56* (9), 1746-1754.
9
10
11 42. Damgaard, C. K.; Andersen, E. S.; Knudsen, B.; Gorodkin, J.; Kjems, J. RNA interactions in the
12 5' region of the HIV-1 genome. *J. Mol. Biol.* **2004**, *336* (2), 369-379.
13
14
15 43. Stephenson, J. D.; Li, H. T.; Kenyon, J. C.; Symmons, M.; Klenerman, D.; Lever, A. M. L. Three-
16 dimensional RNA structure of the major HIV-1 packaging signal region. *Structure* **2013**, *21* (6), 951-
17 962.
18
19
20
21 44. Huthoff, H.; Berkhout, B. Mutations in the TAR hairpin affect the equilibrium between alternative
22 conformations of the HIV-1 leader RNA. *Nucleic Acids Res.* **2001**, *29* (12), 2594-2600.
23
24
25 45. Bardaro, M. F.; Shajani, Z.; Patora-Komisarska, K.; Robinson, J. A.; Varani, G. How binding of
26 small molecule and peptide ligands to HIV-1 TAR alters the RNA motional landscape. *Nucleic Acids*
27 *Res.* **2009**, *37* (5), 1529-1540.
28
29
30 46. Davidson, A.; Leeper, T. C.; Athanassiou, Z.; Patora-Komisarska, K.; Karn, J.; Robinson, J. A.;
31 Varani, G. Simultaneous recognition of HIV-1 TAR RNA bulge and loop sequences by cyclic peptide
32 mimics of Tat protein. *Proc. Natl. Acad. Sci. U.S.A.* **2009**, *106* (29), 11931-11936.
33
34
35 47. Leeper, T. C.; Athanassiou, Z.; Dias, R. L. A.; Robinson, J. A.; Varani, G. TAR RNA recognition
36 by a cyclic peptidomimetic of Tat protein. *Biochemistry* **2005**, *44* (37), 12362-12372.
37
38
39 48. Nowick, J. S.; Khakshoor, O.; Hashemzadeh, M.; Brower, J. O. DSA: A new internal standard
40 for NMR studies in aqueous solution. *Org. Lett.* **2003**, *5* (19), 3511-3513.
41
42
43 49. Mitra, S.; Shcherbakova, I. V.; Altman, R. B.; Brenowitz, M.; Laederach, A. High-throughput
44 single-nucleotide structural mapping by capillary automated footprinting analysis. *Nucleic Acids Res.*
45 **2008**, *36* (11), e63.
46
47
48 50. Badorrek, C. S.; Weeks, K. M. Architecture of a gamma retroviral genomic RNA dimer.
49 *Biochemistry* **2006**, *45* (42), 12664-12672.
50
51
52 51. Darty, K.; Denise, A.; Ponty, Y. VARNA: Interactive drawing and editing of the RNA secondary
53 structure. *Bioinformatics* **2009**, *25* (15), 1974-1975.
54
55
56 52. Fulmer, G. R.; Miller, A. J. M.; Sherden, N. H.; Gottlieb, H. E.; Nudelman, A.; Stoltz, B. M.;
57 Bercaw, J. E.; Goldberg, K. I. NMR chemical shifts of trace impurities: common laboratory solvents,
58
59
60

1 organics, and gases in deuterated solvents relevant to the organometallic chemist. *Organometallics*
2 **2010**, *29* (9), 2176-2179.
3
4
5
6
7
8
9
10

11 **Scheme and Table titles and Figure captions**

12 **Scheme 1.** Synthetic route to **1**^a

13 **Scheme 2.** Synthetic routes to (A) pyridinyl analogs **2-4** (B) **5-10**^a

14 **Scheme 3.** Synthetic route to **11-14**^a

15 **Scheme 4.** Synthetic route to oxadiazole analogs **15-19**^a

16 **Table 1.** Affinity measurement and Tat/TAR displacement assay for **1** and analogs


17 **Figure 1.** (A) Secondary structure of 29nt TAR hairpin with the sites of 2AP replacement highlighted.
18 Constructs were designed with either U23 or U25 replaced with 2-AP. Binding curves from (B) 25-2AP
19 and (C) FRET assays for **2** and **15**.

20 **Figure 2.** (A) Ligand-detected ¹H NMR spectra of aromatic region of **2** (150 μM) and (B) **14** (150 μM) in
21 the presence (red spectra) and absence of TAR hairpin (10 μM) (black spectra).


22 **Figure 3.** Overlaid 2D TOCSY NMR spectra of pyrimidine residues of TAR (A) with increasing
23 concentrations of **2**. Indicated are free TAR (black) and TAR:**2** ratio of 1:1 (green), 1:2 (light blue), 1:3
24 (dark blue), and 1:5 (red). Arrows indicate the direction of chemical shift changes upon addition of **2**. (B)
25 Secondary structure of 29nt TAR hairpin with bases perturbed in the presence of **2** highlighted with red
26 circles.

27 **Figure 4.** SHAPE analysis of the HIV-1 5' UTR in the presence of (A) **2** and (B) **15**, respectively. top:
28 nucleotides are color-coded according to normalized SHAPE reactivity values. 1M7 reactivity of the
29 extreme 5' and 3' terminal nucleotides (represented in white) are not assigned due to limited resolution
30 in the immediate vicinity of the primer and the final extension product. Nucleotide 1 is vector derived.
31 bottom: step plots for quantitative comparison of 1M7 reactivity values obtained from the HIV-1 RNA 5'


1
2 UTR probed in the presence (black) or absence (red) of tested analog. Boxed region corresponds to
3
4 nucleotides involved in formation of the 5' TAR hairpin (nts G2–C58).
5
6
7




^a Reagents and conditions: (a) thiourea, n-BuOH, reflux, 3 h, quantitative; (b) bromoacetyl bromide, DMAP, DCM, 0 °C to rt, 12 h, 88%; (c) NaOEt, EtOH, reflux, 1 h, 58%.



^a Reagents and conditions: (a) bromoacetyl bromide, DCM, rt, 3-12 h, 55%-95%; (b) **25**, NaOEt, EtOH, reflux, 12 h, 32%-46%; (c) thiourea, n-BuOH, reflux, 3 h, quantitative; (d) Lawesson's reagent, toluene, reflux, 4 h 30 min, 42%; (e) bromoacetyl bromide, DMAP, DCM, 0 °C to rt, 6-12 h, 62%-94%; (f) NaOEt, EtOH, reflux, 1 h, 23%-78%.



^a Reagents and conditions: (a) 50% aq. H₃PO₂, conc. H₂SO₄, Cu₂O, 1M aq. NaNO₂, MeOH, 0 °C to rt, 2 h 30 min, 22%; (b) triphosgene, THF, rt, 1 h, 98%; (c) chloromethylsulfonyl chloride, Et₃N, DCM, 0 °C to rt, 12 h then 2N NaOH, rt, 2 h 30 min, 60%-72%; (d) **25**, NaOEt, DMF, 130 °C, 1 h, 33%-72%.




^a Reagents and conditions: (a) **25** or 2-mercaptopyridine-3-carbonitrile (**38**), NaOEt, DMF, 130 °C, 1 h, 31%-76%.


Compound	25-2AP TAR $K_{d,app}$ (μM) ^a	23-2AP TAR $K_{d,app}$ (μM) ^a	FRET IC ₅₀ (μM) ^a
1	47.7 ± 11.6	54.1 ± 5.8	>400
2	40.0 ± 0.7	51.1 ± 5.5	>400
3	68.0 ± 26.0	89.5 ± 7.3	>400
4	50.3 ± 10.3	64.3 ± 2.8	>400
5	66.5 ± 4.5	94.1 ± 20.6	>400
6	48.5 ± 5.4	55.4 ± 9.6	>400
7	75.3 ± 9.2	84.1 ± 9.6	87.0 ± 2.6
8	90.1 ± 4.7	>400	90.4 ± 23.3
9	66.4 ± 0.9	69.4 ± 14.2	>400
10	43.3 ± 13.3	107.1 ± 35.4	>400
11	> 400	>400	>400
12	>400	>400	>400
13	>400	>400	>400
14	>400	>400	>400
15	49.1 ± 7.8	75.0 ± 15.4	40.1 ± 5.6
16	47.7 ± 17.8	46.0 ± 15.2	45.1 ± 25.8
17	44.6 ± 7.9	56.9 ± 8.1	>300
18	42.5 ± 2.9	45.6 ± 7.8	>400
19	50.2 ± 8.4	44.1 ± 9.0	37.6 ± 13.1

^aHighest concentration evaluated was 400 μM unless otherwise indicated. Values represent the average of three replicates, \pm standard deviation.


A




B




C




A




B





19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

B








Table of Contents Graphic



Binding site identified by TOCSY NMR